Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access

Experts present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.

Overview
In an evolving healthcare environment with constant economic pressures, there is an increasing need to generate robust and actionable payer insights, beginning in the early stages of development and continuing all the way to post-launch. Actionable payer insights facilitate an informed approach to evidence generation that will be meaningful to payer, HTA, and medical decision-makers.

This webinar is designed to inform HEOR, RWE, and market access leads in pharmaceutical, biotech, and medical device companies.

Full Description
In an evolving healthcare environment with constant economic pressures, clinical innovation alone is not sufficient to achieve optimal reimbursement and patient access.

Payers, regulators, and health technology assessment (HTA) agencies prioritize products that demonstrate the most compelling clinical benefit versus risk, as well as economic value, and increasingly are prioritizing benefits to patients.

Strategically timed payer insights can inform a relevant and timely evidence package and drug development strategy by defining the data required to support an optimal place in therapy/treatment pathways and by describing the value of the product in populations of unmet need. Understanding the evolving competitive and HTA landscape facilitates a forward-thinking approach to evidence strategies across the product lifecycle and increases the likelihood of optimal access.

In such a dynamic healthcare environment, the utilization of agile platforms and fit-for-purpose engagement models can drive an efficient and iterative approach to payer insights, evidence-synthesis, and evidence-generation. These approaches allow for flexibility and agility, and ensure that the process can be accelerated without compromising scientific rigor, facilitating the generation of evidence packages that are relevant and important for decision-makers.